Free Shipping on orders over $99

Proton Pump Inhibitors for GORD

Digestion, General | March 1, 2016 | Author: The Super Pharmacist


Proton Pump Inhibitors for GORD

Gastro-oesophageal reflux disease (GORD) is a condition in which stomach acid 'backs up' into the oesophagus, or the tube connecting the mouth to the rest of the gastro-intestinal system1. This disorder, also known as GERD or acid reflux, may cause the taste of acid or bile in the back of the throat, discomfort, and pain in severe cases1. GORD may be mild, moderate or chronic, and may also increase the risk of other gastrointestinal disorders. The development of Barrett's oesophagus, a condition in which the cells of this tube are transformed or altered in a way that makes them resemble cells of the small intestine, may be influenced by pre-existing GORD2. This disorder, in turn, increases the risk of cancer in the upper gastric tract3,4. Other consequences of GORD include inflammation and wearing away of the lining of the oesphagus over time, which may lead to blood loss1. The prevalence of GORD may be as high as 20% in Europe and North America1. GORD may develop as a result of the decreased integrity of the connection between the oesophagus and stomach. This is mostly controlled by the lower oesophageal sphincter, a muscular valve that should relax to allow food into the stomach, and then contract when eating (or rather swallowing) has stopped. However, in the course of the progression of GORD, this valve becomes increasingly relaxed at inappropriate times, which may result in the involuntary regurgitation of acid (and possibly undigested food particles) back up into the throat5. This is known as transient lower oesophageal sphincter relaxation5. The risk of developing GORD may be affected by many factors and other conditions. These include:

  • Cystic fibrosis: Up to 80% of cystic fibrosis patients may have increased acid reflux6. This may be due to decreased pressure of the lower oesophageal sphincter5.
  • Pregnancy: Approximately 66% of women may develop GORD while pregnant7. This may be due to impaired stomach capacity, digestion and the reduced function of muscles that control swallowing8-10.
  • Lifestyle choices: Habitual tobacco-smoking or regular alcohol intake is also associated with the increased risk of developing GORD11,12.
  • Diet: Some foods have been known to increase the risk of GORD. These include fatty foods, caffeinated drinks, soft drinks, chocolate and spicy food. Additionally, portion control is an important component of reducing GORD, as over consumption can lead to symptoms of GORD.

Treatment For GORD

Proton Pump Inhibitors for GORDGORD may be treated with a variety of therapies and strategies. These include:

Lifestyle and dietary modifications

Intermittent eating patterns are strongly associated with the development of GORD. Snacking between meals may further distend the stomach and increase lower oesophageal sphincter relaxation13. This may be addressed by implementing and maintaining a more regular meal-based eating regimen, with reduced snacking and more fluids between meals13. Weight loss may be associated with an improved response to treatment in patients with GORD14. In the case of GORD during pregnancy, the pressure on the stomach may be alleviated by taking increased amounts of small meals during the day, rather than three or four larger ones15. GORD may occur while sleeping; therefore, raising the head of a bed by about 15cm to reduce mechanical stress on the stomach during this time, may be helpful16,17. Patients with GORD may also benefit from a reduced intake of acidic foods and polyunsaturated fatty acids6.


These are products containing such ingredients as sodium bicarbonate or calcium carbonate, which can neutralise hydrochloric acid (HCl), which is produced in the stomach to break down food, and may be pushed back up through the oesophagus in an attack of GORD18. Pregnant women should not take antacids containing sodium bicarbonate, as they may increase water retention19.

Proton Pump Inhibitors for GORDHistamine Blockers

These are histamine receptor-2 (H2) antagonists, that can prevent the production of HCl from cells in the stomach lining18. This will reduce the availability of acid to irritate or inflame the oesophagus at the onset of GORD. The most common choice is ranitidine.

Proton Pump Inhibitors

If the above treatment options fail or patients require long-term relief, patients may be advised to switch to proton pump inhibitors (PPI's). These drugs also reduce stomach acid production by decreasing the availability of the molecular 'raw materials' required by cells to do so. There are several types of proton pump inhibitors available. These include1; Pantoprazole, Esomeprazole, Lansoprazole, Omeprazole and Rabeprazole. Proton pump inhibitors are indicated for many symptoms and complications of GORD, including:

1. Symptoms without complications A systematic review of 3 trials of proton pump inhibitors found that esomeprazole (20mg), omeprazole (20mg), pantoprazole (20mg) and rabeprazole (10mg) were equally effective in treating reflux without inflammation or eosophageal lining damage20. The data on complete symptom resolution is limited in both quality and quantity, but indicates that all five subtypes are equally effective in this20. Lower doses of these drugs may be recommended for long-term therapy due to the risks of side-effects21. A review of 11 studies indicated that there was no difference in the long-term symptom management of high- and low- dose lansoprazole. However, remission times for high-dose rabeprazole and omeprazole were superior to those of lower doses of the same drugs20. There was no conclusive data on these differences between high- and low-dose omeprazole20.

2. Oesophageal inflammation and/or oesophageal damage These complications, also known as oesophagitis, may also be treated with proton pump inhibitors. A review of 16 trials found no difference between the various subtypes in relieving oesophagitis20. Esomerprazole (40mg) was found to be more effective in the healing of moderate to severe oesophagitis at 4 weeks (but not 8 weeks) into treatment compared to an equal dose of pantoprazole20. This dose of esomerprazole was also found to be superior to lansoprazole (30mg) and omeprazole (20mg). Rabeprazole, omeprazole and lansoprazole were found to be equally effective in promoting the remission of inflammation. Two studies found that pantoprazole (20mg) had a higher rate of relapse in this complication compared to the same concentration of esomeprazole. Systematic review of these drugs indicates that they are generally comparable in efficacy, safety and side-effect profiles20. The data on which proton pump inhibitor is associated with the highest incidence of adverse effects is poor and limited20. However, this indicates that all five subtypes have an equal probability of these, which may include diarrhoea, an increased risk of gastric bleeding or cancer, pneumonia and bone fractures20,21. On the other hand, pantoprazole is regarded as having a higher bioavailability and a lower rate of interaction with other drugs22. These interactions may include an increased risk of cardiovascular events when taken with clopidogrel. However, a recent clinical trial showed that the co-administration of omeprazole with this drug reduced the risk of gastrointestinal bleeding without an increase in cardiovascular risk21. Australia's best online pharmacy


  1. Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World journal of gastrointestinal pharmacology and therapeutics. 2014;5(3):105-112.
  2. DeMeester SR, DeMeester TR. The diagnosis and management of Barrett's esophagus. Advances in surgery. 1999;33:29-68.
  3. Haidry R, Banks M, Gupta A, et al. OC-014 Patients With Intramucosal Carcinoma Arising In Barrett's Eosophagus Have Similar Outcomes To Those With High Grade Dysplasia: Data From The United Kingdom Registry. Gut. 2014;63 Suppl 1:A7.
  4. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2011;15(5):708-718.
  5. Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. The American journal of gastroenterology. 2012;107(9):1346-1353.
  6. Dall'Alba V, Fornari F, Krahe C, Callegari-Jacques SM, Silva de Barros SG. Heartburn and regurgitation in pregnancy: the effect of fat ingestion. Digestive diseases and sciences. 2010;55(6):1610-1614.
  7. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterology clinics of North America. 2003;32(1):235-261.
  8. Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best practice & research. Clinical gastroenterology. 2007;21(5):793-806.
  9. Anton C, Anton E, Drug VL, Stanciu C. [Hormonal influence on gastrointestinal reflux during pregnancy]. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2003;107(4):798-801.
  10. Pouderoux P, Verdier E, Kahrilas PJ. Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. American journal of physiology. Gastrointestinal and liver physiology. 2003;284(2):G242-247.
  11. Slomski A. Gastroesophageal reflux symptoms abate when smoking stops. JAMA : the journal of the American Medical Association. 2014;311(4):349.
  12. Rubenstein JH, Chen JW. Epidemiology of gastroesophageal reflux disease. Gastroenterology clinics of North America. 2014;43(1):1-14.
  13. Yasawy MI, Randhawa MA. GERD is becoming a challenge for the medical profession: is there any remedy? Hepatogastroenterology. 2014;61(134):1623-1626.
  14. de Bortoli N, Guidi G, Martinucci I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E. 2014.
  15. Fill S, Malfertheiner M, Costa SD, Monkemuller K. [Handling of the gastroesophageal reflux disease (GERD) during pregnancy--a review]. Zeitschrift fur Geburtshilfe und Neonatologie. 2007;211(6):215-223.
  16. Galdon Castillo A, Galera Mendoza L, Egea Gonzalez A, Gonzalez Olsen A, Sanchez Gonzalez Y, Paniagua Soto J. [Disorders affecting the digestive system during sleep]. Revista de neurologia. 2004;38(8):757-765.
  17. Csendes A, Burdiles P. [Scientific foundations for medical treatment based on modifying diet, lifestyle habits, and patient attitudes in chronic gastroesophageal reflux disease]. Cirugia espanola. 2007;81(2):64-69.
  18. McRorie JW, Jr., Gibb RD, Miner PB, Jr. Evidence-based treatment of frequent heartburn: The benefits and limitations of over-the-counter medications. Journal of the American Association of Nurse Practitioners. 2014;26(6):330-339.
  19. Quartarone G. Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents. Minerva ginecologica. 2013;65(5):541-549.
  20. McDonagh MS, Carson S, Thakurta S. Drug Class Reviews. Drug Class Review: Proton Pump Inhibitors: Final Report Update 5. Portland (OR): Oregon Health & Science University, Portland, Oregon; 2009.
  21. Abraham NS. Proton pump inhibitors: potential adverse effects. Current opinion in gastroenterology. 2012;28(6):615-620.
  22. [Comparison of the effectiveness omeprazole and pantoprazole in the treatment of gastroesophageal reflux disease in patients with asthma]. Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy. 2013(6):47-53.
backBack to Blog Home